Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer (ONCOVID-AURA)
ONCOVID-AURA: Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer
Context:
Based on currently available data, most of national health authorities and consensus expert groups have written guidelines for the management of cancer patients in the context of COVID. However, the preparation of these guidelines was limited by the scarcity of solid epidemiological data. For example, the experts were uncomfortable to formulate precise guidelines on which anti-cancer treatment should be interrupted or replaced, on which patients, and how to adapt supportive drug prescriptions.
Objectives :
- To measure the excess risk of mortality and morbidity of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection.
- To identify factors associated with the risk of death and morbidity among patients with cancer.
Methodology:
Retrospective inclusion of n=200 cancer patients hospitalized for COVID and n=400 matched (based on age, gender, and comorbidity) non-cancer patients hospitalized for COVID. Two analyses will be performed (after the inclusion of n=100 and n=200 patients with cancer). A logistic modeling of the odds ratio of death associated to the exposition factor (i.e. cancer) and adjusted for the matching parameters (age, gender, comorbidities) will be proposed.
We will then look for the factors (related to the patients, the cancer or the treatment) that modify the odds radio.
Expected results:
The data generated will help the medical and scientific community to evaluate the increasing risk of cancer patients infected by SARS-CoV-2 compared to the non-cancer population, to identify patients at higher risk of severe infection, but also the anticancer treatments associated with an increased risk of severe infections.
Impact:
These data will contribute to guide the future recommendations concerning cancer patient's care in the context of the COVID-19 pandemic. There is a real risk that the SARS-CoV epidemic, or other respiratory viruses epidemic, will become recurrent in the future. Thus, it is of crucial importance for now and for the future to know which are the major factors associated with severe infections
調査の概要
研究の種類
入学 (予想される)
連絡先と場所
研究連絡先
- 名前:PERRON Julien, MD
- 電話番号:+33 (0)4 78 86 37 75
- メール:julien.peron@chu-lyon.fr
研究連絡先のバックアップ
- 名前:CALATTINI Sarah
- 電話番号:+33 (0) 4 78 86 37 79
- メール:sara.calattini@chu-lyon.fr
研究場所
-
-
-
Clermont-Ferrand、フランス
- 募集
- Centre de Lutte Contre le Cancer Jean PERRIN
-
コンタクト:
- PERRON Julien, MD
-
Clermont-Ferrand、フランス
- 募集
- Centre Hospitalier Uniersitaire de Clermont-Ferrand
-
コンタクト:
- BAY Jacques Olivier, MD
-
Lyon、フランス
- 募集
- Centre Léon Bérard
-
コンタクト:
- PEROL David, Pr
-
Saint-Priest-en-Jarez、フランス
- 募集
- Institut de Cancérologie de la Loire Lucien Neurwirth
-
コンタクト:
- FOURNEL Pierre, MD
-
Saint-Étienne、フランス
- 募集
- Centre Hospitalier Universitaire de St Etienne
-
コンタクト:
- Botelho-Nevers Elisabeth, PR
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Two categories of patients will be defined: the "exposed patients" are patients with cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection. A patient will be considered as an "exposed patient" if he/she had a surgical procedure or a medical treatment for cancer in the past 5 years preceding the SARS-CoV-2 infection.
The "control patients" are all of the patients without cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection.
In both cohorts, a positive laboratory test (RT-PCR) proving the SARS-CoV-2 infection will be mandatory.
説明
Inclusion Criteria:
- EXPOSED PATIENTS:
- Age > 18 years old
- Patients with a confirmed diagnosis of solid or hematologic cancer
- Patients who received their last anticancer treatment (surgery, systemic treatments or other localized treatment) in the past 5 years before SARS-CoV-2 infection
- Positive laboratory test (RT-PCR) proving the SARS-CoV-2 infection
- Patients hospitalized in one of the participating centers because of the SARS-CoV-2 infection
- Patients who are not opposed in participating to the ONCOVID-AURA study
CONTROL PATIENTS:
- Age > 18 years old
- Patients who have no cancer (neither solid nor hematologic tumors) or patients who received their last anticancer treatments more than five years before the SARS-CoV-2 infection
- Positive laboratory test (RT-PCR) proving the SARS-CoV-2 infection
- Patients hospitalized in one of the participating centers because of the SARS-CoV-2 infection
- Patients who are not opposed in participating to the ONCOVID-AURA study
Exclusion Criteria:
- none
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
---|---|
exposed patients
The "exposed patients" are patients with cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection.
A patient will be considered as an "exposed patient" if he/she had a surgical procedure or a medical treatment for cancer in the past 5 years preceding the SARS-CoV-2 infection.
|
To measure the excess risk of mortality of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection
|
control patients
The "control patients " are all of the patients without cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection
|
To measure the excess risk of mortality of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
mortality for SARS-CoV-2 infection
時間枠:30 days
|
mortality within 30 days after the hospitalization for the SARS-CoV-2 infection
|
30 days
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 69HCL20_0509
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
COVID, Cancerの臨床試験
-
Indonesia University募集COVID-19後症候群 | 長い COVID | COVID-19 後の状態 | COVID後症候群 | 長い COVID-19インドネシア
-
European Institute of OncologyFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; Azienda Ospedaliera Niguarda Cà Granda; Papa Giovanni XXIII Hospital と他の協力者完了
-
Owlstone LtdCambridge University Hospitals NHS Foundation Trust完了
-
Endourage, LLC募集長い COVID | ロング Covid19 | ポスト急性COVID-19 | 長距離COVID | 長距離COVID-19 | ポスト急性COVID-19症候群アメリカ
-
Massachusetts General Hospital募集
-
Erasmus Medical CenterDa Vinci Clinic; HGC Rijswijkまだ募集していませんCOVID-19後症候群 | 長い COVID | ロング Covid19 | COVID-19 後の状態 | COVID後症候群 | COVID-19 後の状態、詳細不明 | 新型コロナウイルス感染症後の状況オランダ
-
Medical University of Vienna募集迷走神経疾患 | COVID-19後症候群 | 長い COVID | ロング Covid19 | COVID-19 後の状態 | COVID後症候群 | COVID後の状態オーストリア
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, Indonesia募集COVID-19 パンデミック | COVID-19 ワクチン | COVID-19 ウイルス病インドネシア